53 related articles for article (PubMed ID: 31349217)
1. Treatment and long-term outcomes in pituitary carcinoma: a cohort study.
Santos-Pinheiro F; Penas-Prado M; Kamiya-Matsuoka C; Waguespack SG; Mahajan A; Brown PD; Shah KB; Fuller GN; McCutcheon IE
Eur J Endocrinol; 2019 Oct; 181(4):397-407. PubMed ID: 31349217
[TBL] [Abstract][Full Text] [Related]
2. Genetic aspects of pituitary carcinoma: A systematic review.
Yang Z; Zhang T; Gao H
Medicine (Baltimore); 2016 Nov; 95(47):e5268. PubMed ID: 27893664
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of Temozolomide Therapy in Patients With Aggressive Pituitary Adenomas and Carcinomas-A German Survey.
Elbelt U; Schlaffer SM; Buchfelder M; Knappe UJ; Vila G; Micko A; Deutschbein T; Unger N; Lammert A; Topuzoglu-Müller T; Bojunga J; Droste M; Johanssen S; Kolenda H; Ritzel K; Buslei R; Strasburger CJ; Petersenn S; Honegger J
J Clin Endocrinol Metab; 2020 Mar; 105(3):. PubMed ID: 31746334
[TBL] [Abstract][Full Text] [Related]
4. Approach to the Treatment of a Patient with an Aggressive Pituitary Tumor.
Lin AL; Donoghue MTA; Wardlaw SL; Yang TJ; Bodei L; Tabar V; Geer EB
J Clin Endocrinol Metab; 2020 Dec; 105(12):3807-20. PubMed ID: 32930787
[TBL] [Abstract][Full Text] [Related]
5. The Progress of Immunotherapy in Refractory Pituitary Adenomas and Pituitary Carcinomas.
Dai C; Liang S; Sun B; Kang J
Front Endocrinol (Lausanne); 2020; 11():608422. PubMed ID: 33362722
[TBL] [Abstract][Full Text] [Related]
6. Long-course temozolomide in aggressive pituitary adenoma: real-life experience in two tertiary care centers and review of the literature.
Lizzul L; Lombardi G; Barbot M; Ceccato F; Gardiman MP; Regazzo D; Bellu L; Mazza E; Losa M; Scaroni C
Pituitary; 2020 Aug; 23(4):359-366. PubMed ID: 32232709
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of pembrolizumab in patients with pituitary carcinoma: report of four cases from a phase II study.
Majd N; Waguespack SG; Janku F; Fu S; Penas-Prado M; Xu M; Alshawa A; Kamiya-Matsuoka C; Raza SM; McCutcheon IE; Naing A
J Immunother Cancer; 2020 Dec; 8(2):. PubMed ID: 33427689
[TBL] [Abstract][Full Text] [Related]
8. Update on Current Evidence for the Diagnosis and Management of Nonfunctioning Pituitary Neuroendocrine Tumors.
Whyte E; Nezu M; Chik C; Tateno T
Endocrinol Metab (Seoul); 2023 Dec; 38(6):631-654. PubMed ID: 37964483
[TBL] [Abstract][Full Text] [Related]
9. Metastatic pituitary tumors: an institutional case series.
Yearley AG; Chalif EJ; Gupta S; Chalif JI; Bernstock JD; Nawabi N; Arnaout O; Smith TR; Reardon DA; Laws ER
Pituitary; 2023 Oct; 26(5):561-572. PubMed ID: 37523025
[TBL] [Abstract][Full Text] [Related]
10. Benign and Malignant Tumors of the Pituitary Gland.
Albano L; Losa M; Barzaghi LR; Mortini P
Adv Exp Med Biol; 2023; 1405():281-297. PubMed ID: 37452942
[TBL] [Abstract][Full Text] [Related]
11. The Role of Immunotherapy in the Treatment of Rare Central Nervous System Tumors.
Rodriguez A; Kamiya-Matsuoka C; Majd NK
Curr Oncol; 2023 May; 30(6):5279-5298. PubMed ID: 37366884
[TBL] [Abstract][Full Text] [Related]
12. Recent Therapeutic Advances in Pituitary Carcinoma.
Robertson IJ; Gregory TA; Waguespack SG; Penas-Prado M; Majd NK
J Immunother Precis Oncol; 2023 May; 6(2):74-83. PubMed ID: 37214211
[TBL] [Abstract][Full Text] [Related]
13. Aggressive Pituitary Tumors and Pituitary Carcinomas: From Pathology to Treatment.
Burman P; Casar-Borota O; Perez-Rivas LG; Dekkers OM
J Clin Endocrinol Metab; 2023 Jun; 108(7):1585-1601. PubMed ID: 36856733
[TBL] [Abstract][Full Text] [Related]
14. Editorial: Refractory Pituitary Adenoma-Current Challenges and Emerging Treatments.
Wang R; Zhou C; McCormack AI; Mamelak AN
Front Endocrinol (Lausanne); 2022; 13():868174. PubMed ID: 35355554
[No Abstract] [Full Text] [Related]
15. Temozolomide Nonresponsiveness in Aggressive Prolactinomas and Carcinomas: Management and Outcomes.
Das L; Rai A; Salunke P; Ahuja CK; Sood A; Radotra BD; Sood R; Korbonits M; Dutta P
J Endocr Soc; 2022 Feb; 6(2):bvab190. PubMed ID: 35059545
[TBL] [Abstract][Full Text] [Related]
16. Early Initiation of Temozolomide Therapy May Improve Response in Aggressive Pituitary Adenomas.
Das L; Gupta N; Dutta P; Walia R; Vaiphei K; Rai A; Radotra BD; Gupta K; Sreedharanunni S; Ahuja CK; Bhansali A; Tripathi M; Sood R; Dhandapani S
Front Endocrinol (Lausanne); 2021; 12():774686. PubMed ID: 34975752
[TBL] [Abstract][Full Text] [Related]
17. Treatment of Aggressive Pituitary Adenomas: A Case-Based Narrative Review.
Cooper O; Bonert V; Liu NA; Mamelak AN
Front Endocrinol (Lausanne); 2021; 12():725014. PubMed ID: 34867776
[TBL] [Abstract][Full Text] [Related]
18. Aggressive pituitary tumours and pituitary carcinomas.
Raverot G; Ilie MD; Lasolle H; Amodru V; Trouillas J; Castinetti F; Brue T
Nat Rev Endocrinol; 2021 Nov; 17(11):671-684. PubMed ID: 34493834
[TBL] [Abstract][Full Text] [Related]
19. Clinical Efficacy of Temozolomide and Its Predictors in Aggressive Pituitary Tumors and Pituitary Carcinomas: A Systematic Review and Meta-Analysis.
Luo M; Tan Y; Chen W; Hu B; Wang Z; Zhu D; Jiao H; Duan C; Zhu Y; Wang H
Front Neurol; 2021; 12():700007. PubMed ID: 34220696
[No Abstract] [Full Text] [Related]
20. Pituitary neuroendocrine tumors: a model for neuroendocrine tumor classification.
Asa SL; Mete O; Cusimano MD; McCutcheon IE; Perry A; Yamada S; Nishioka H; Casar-Borota O; Uccella S; La Rosa S; Grossman AB; Ezzat S;
Mod Pathol; 2021 Sep; 34(9):1634-1650. PubMed ID: 34017065
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
